The FAST study that pitted febuxostat against allopurinol for patients with gout and CVD risk factors has released its results in a late breaking abstract at ACR. Thomas MacDonald, the senior author and a professor of medicine at the University of Dundee in the UK, came on the Rheumatology Republic podcast to discuss the study.